MedicarePartD.guide

A non-government resource built from CMS public data

IL-17, IL-23 and IL-12/23 biologics on every 2026 New York Part D plan

Pick a drug class, or type the drugs you want to check, and see which of the 10 stand-alone Part D plans in New York cover each one, on what tier, and with what restrictions.

A class overrides typed names. Separate names with commas; brand or generic both work.

  • Covered
  • Covered, needs prior authorization (PA) or step therapy (ST)
  • Not on the formulary
  • QL 60/30d = quantity limit, 60 units per 30 days
IL-17, IL-23 and IL-12/23 biologics by 2026 New York Part D plan
DrugHealthSpring Assurance Rx$35.70/moS5617-013Wellcare Value Script$42.40/moS4802-138Wellcare Classic$45.70/moS4802-077HealthSpring Extra Rx$91.60/moS5617-353AARP Medicare Rx Saver from UHC$105.80/moS5921-379SilverScript Choice$116.00/moS5601-006Humana Basic Rx Plan$140.90/moS5884-216Humana Value Rx Plan$158.90/moS5884-218AARP Medicare Rx Preferred from UHC$163.70/moS5921-382Humana Premier Rx Plan$173.60/moS5884-217
StelaraustekinumabTier 5PA25%QL 0.5/28dNot coveredNot coveredTier 5PA25%QL 0.5/28dNot coveredTier 5PA25%QL 0.5/28dTier 5PA25%QL 1.5/84dTier 5PA26%QL 1.5/84dNot coveredTier 5PA33%QL 1.5/84d
ustekinumab biosimilarsWezlana, Selarsdi, Pyzchiva and othersTier 5PA25%QL 0.5/28dNot coveredNot coveredTier 5PA25%QL 0.5/28dNot coveredTier 5PA25%QL 0.5/28dTier 5PA25%QL 1.5/84dTier 5PA26%QL 1.5/84dNot coveredTier 5PA33%QL 1.5/84d
Wezlanaustekinumab-auubNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
Selarsdiustekinumab-aeknTier 3PA25%QL 0.5/28dNot coveredNot coveredTier 3PA17%QL 0.5/28dNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
SkyrizirisankizumabTier 5PA25%QL 2/28dTier 5PA25%QL 6/365dTier 5PA25%QL 6/365dTier 5PA25%QL 2/28dTier 5PA25%QL 1/28dTier 5PA25%QL 6/365dTier 5PA25%QL 2/84dTier 5PA26%QL 2/84dTier 5PA31%QL 1/28dTier 5PA33%QL 2/84d
TremfyaguselkumabTier 5PA25%QL 2/28dTier 5PA25%QL 2/28dTier 5PA25%QL 2/28dTier 5PA25%QL 2/28dTier 5PA25%Tier 5PA25%QL 1/28dTier 5PA25%QL 3/84dTier 5PA26%QL 3/84dTier 5PA31%Tier 5PA33%QL 3/84d
CosentyxsecukinumabTier 5PA25%QL 10/28dTier 5PA25%QL 10/28dTier 5PA25%QL 10/28dTier 5PA25%QL 10/28dTier 5PA25%QL 10/30dNot coveredTier 5PA25%QL 8/28dTier 5PA26%QL 8/28dTier 5PA31%QL 10/30dTier 5PA33%QL 8/28d
TaltzixekizumabNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
BimzelxbimekizumabNot coveredNot coveredNot coveredNot coveredNot coveredTier 5PA25%QL 4/28dNot coveredNot coveredNot coveredNot covered

Where a plan covers several strengths or forms of a drug, the cell shows the least restricted one. Costs are the 30-day preferred-pharmacy cost-sharing in the initial coverage phase, from the CMS 2026 formulary files. Click a plan for its full drug list.